HomeQuestion

Can you extrapolate the PROTEUS data and replace apalutamide with other ARPIs for high-risk localized or locally advanced prostate cancer if approved?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?

For mCRPC patients who are eligible for both, how do you decide between Enzalutamide+Rad223 (EORTC 1333/PEACE-3) or Enzalutamide+Lu-PSMA-617 (ENZA-p)?

How does the POSEIDON meta-analysis results influence your decision on which patients should receive hormone therapy with post-operative radiotherapy for recurrent prostate cancer?

What are your top takeaways from ASCO GU 2026?

Is the PROTEUS data enough to change your practice in the treatment of patients with high-risk localized or locally advanced prostate cancer?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.